Amendments to S.3187, the FDA user fees bill
The following amendments have been considered to S.3187, the FDA user fees bill:
- Harkin-Enzi amendment #2122 (substitute); agreed to by unanimous consent
- Cardin amendment #2125 (health benefits/risks); agreed to by unanimous consent
- Cardin amendment #2141 (FDA report-small business); agreed to by unanimous consent
- Grassley amendment #2121 (whistleblower protections III); agreed to by unanimous consent
- Grassley amendment #2129 (GAO report - clinical trials)
- Manchin amendment #2151, as modified (reclassification of hydrocodone under Controlled Substances Act); agreed to by unanimous consent
- Reed amendment #2126 (Sunscreen testing/labeling); agreed to by unanimous consent
- Leahy amendment #2142, as modified (FOIA); agreed to by unanimous consent
- Portman amendment #2145, as modified (Rx drug monitoring); agreed to by unanimous consent
- Coburn amendment #2131 (drug application review process); agreed to by unanimous consent
- Coburn amendment #2132 (FDA employee performance standards); withdrawn
- Portman amendment #2146, as modified (Synthetic drugs - controlled substances); agreed to by voice vote
- Bingaman amendment #2111 (generic filings) (60-vote threshold); Not agreed to: 28-67
- Murkowski amendment #2108 (genetically engineered salmon); Not Agreed To: 46-50
- Paul amendment #2143 (supplements); Tabled: 78-15
- McCain amendment #2107 (drug reimportation); Not Agreed To: 43-54
- Sanders amendment #2109 (criminal fraud/exclusivity); Not Agreed To: 9-88
- Burr amendment #2130 (Congress - user fee negotiations); Withdrawn
- Durbin amendment #2127 (dietary supplements); Tabled: 77-20
